Disopyramide drug information

Why is this medication prescribed?
How should this medicine be used?
Other uses for this medicine
What special precautions should I follow?
What should I do if I forget a dose?
What side effects can this medication cause?
What should I know about STORAGE and DISPOSAL of this medication?
What should I do in case of OVERDOSE?
What OTHER INFORMATION should I know?
Drug interactions

IMPORTANT WARNING

Taking antiarrhythmic drugs, including disopyramide, may increase the risk of death. Tell your doctor if you have heart disease such as a valve problem or heart failure (HF; condition in which the heart cannot pump enough blood to other parts of the body). If you experience any of the following symptoms, call your doctor immediately: irregular heartbeat or chest pain.

Talk to your doctor about the risks of taking disopyramide. Disopyramide may increase the chance of having arrhythmias (irregular heartbeats) and has not been proven to help people without life-threatening arrhythmias to live longer.

Why is this medication prescribed?

Disopyramide is used to treat certain types of irregular heartbeats). Disopyramide is in a class of medications called antiarrhythmic medications. It works by making your heart more resistant to abnormal activity.

How should this medicine be used?

Disopyramide comes as a capsule and an extended-release (long-acting) capsule to take by mouth. Disopyramide capsules may be taken every 6 or 8 hours. The extended-release capsule is usually taken every 12 hours. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take disopyramide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the extended-release capsules; do not open, crush, or chew them.

Disopyramide helps control your condition but will not cure it. Continue to take disopyramide even if you feel well. Do not stop taking disopyramide without talking to your doctor.

Other uses for this medicine

This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking disopyramide,

tell your doctor and pharmacist if you are allergic to disopyramide, any other medications, or any of the ingredients in disopyramide capsules. Ask your pharmacist for a list of the ingredients.

tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: clarithromycin, erythromycin (E.E.S., Eryc, Erythrocin, others), phenytoin (Dilantin, Phenytek), propranolol (Inderal, Innopran), and verapamil (Calan, Tarka, Verelan). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

tell your doctor if you have heart block (condition in which electrical signals are not passed normally from the upper chambers of the heart to the lower chambers) or have or have ever had a prolonged QT interval (condition that increases the risk of developing an irregular heartbeat that may cause fainting or sudden death). Your doctor may tell you not to take disopyramide.

tell your doctor if you have or have ever had heart disease, low or high blood levels of potassium in your blood, diabetes, glaucoma, myasthenia gravis (a disorder of the nervous system that causes muscle weakness), urinary retention, benign prostatic hypertrophy, kidney or liver disease.

tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while taking disopyramide, call your doctor.

talk to your doctor about the risks and benefits of taking disopyramide if you are 65 years of age or older. Older adults should not usually take disopyramide because it is not as safe or effective as other medications that can be used to treat the same condition.

if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking disopyramide.

ask your doctor about the safe use of alcoholic beverages while you are taking disopyramide. Alcohol can make the side effects from disopyramide worse.

What should I do if I forget a dose?

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

What side effects can this medication cause?

Disopyramide may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
- dizziness or lightheadedness
- difficult urination
- frequent urination
- dry mouth
- constipation
- blurred vision
- nausea
- fatigue
- headache
- weakness
- stomach pain or bloating
- fatigue
- weakness
- headache
- rash

Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately:
- chest pain
- swelling of the feet or hands
- unusual weight gain
- irregular heartbeat
- shortness of breath
- sudden changes in mental status
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

What should I know about STORAGE and DISPOSAL of this medication?

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

What should I do in case of OVERDOSE?

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include:

slow or irregular heartbeat
dry mouth
difficulty urinating
constipation
loss of consciousness

What OTHER INFORMATION should I know?

Keep all appointments with your doctor and the laboratory. Your doctor will need to determine your response to disopyramide.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug interactions

Drug	Interaction
Moxifloxacin	Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Disopyramide.
Repaglinide	Repaglinide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Repaglinide.
Insulin Glargine (rDNA origin) Injection	Insulin Glargine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Disopyramide.
Leflunomide	Leflunomide The serum concentration of Disopyramide can be decreased when it is combined with Leflunomide.
Nevirapine	Nevirapine The metabolism of Disopyramide can be decreased when combined with Nevirapine.
Dolasetron	Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Disopyramide.
Aminophylline	Aminophylline The metabolism of Aminophylline can be decreased when combined with Disopyramide.
Anagrelide	Anagrelide The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Disopyramide.
Bisacodyl	Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Disopyramide.
Cilostazol	Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Disopyramide.
Clopidogrel	Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Disopyramide.
Diphenoxylate	Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Disopyramide.
Erythromycin and Sulfisoxazole	Erythromycin and Sulfisoxazole Erythromycin may increase the QTc-prolonging activities of Disopyramide.
Estrogen and Progestin (Oral Contraceptives)	Estrogen and Progestin (Oral Contraceptives) The metabolism of Conjugated estrogens can be decreased when combined with Disopyramide.
Fenofibrate	Fenofibrate Disopyramide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Guanfacine	Guanfacine Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Magnesium Hydroxide	Magnesium Hydroxide Disopyramide may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium Oxide	Magnesium Oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Disopyramide.
Miglitol	Miglitol The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Miglitol.
Mycophenolate	Mycophenolate Disopyramide may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
Naratriptan	Naratriptan Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Olsalazine	Olsalazine Olsalazine may increase the hypoglycemic activities of Disopyramide.
Paregoric	Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Disopyramide.
Penbutolol	Penbutolol Disopyramide may increase the bradycardic activities of Acebutolol.
Pentazocine	Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Disopyramide.
Polyethylene glycol-electrolyte solution (PEG-ES)	Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Disopyramide.
Potassium	Potassium Potassium may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone	Prednisone The risk or severity of hyperglycemia can be increased when Prednisone is combined with Disopyramide.
Psyllium	Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Disopyramide.
Ranitidine	Ranitidine The risk or severity of adverse effects can be increased when Disopyramide is combined with Ranitidine.
Reserpine	Reserpine Reserpine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Rizatriptan	Rizatriptan Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Rizatriptan.
Sumatriptan	Sumatriptan The therapeutic efficacy of Disopyramide can be increased when used in combination with Sumatriptan.
Tacrolimus	Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Disopyramide.
Tizanidine	Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Disopyramide.
Triamcinolone	Triamcinolone The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Disopyramide.
Zolmitriptan	Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Disopyramide.
Ampicillin Injection	Ampicillin Injection Disopyramide may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Doxycycline Injection	Doxycycline Injection Doxycycline may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Famotidine Injection	Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Disopyramide.
Fluconazole Injection	Fluconazole Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Fluconazole.
Foscarnet Injection	Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Disopyramide.
Hydromorphone Injection	Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Disopyramide.
Interferon Beta-1b Injection	Interferon Beta-1b Injection The metabolism of Disopyramide can be decreased when combined with Interferon beta-1b.
Interferon Gamma-1b Injection	Interferon Gamma-1b Injection The metabolism of Disopyramide can be decreased when combined with Interferon gamma-1b.
Levofloxacin Injection	Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Disopyramide.
Meperidine Injection	Meperidine Injection The risk or severity of adverse effects can be increased when Meperidine is combined with Disopyramide.
Methylprednisolone Injection	Methylprednisolone Injection The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Disopyramide.
Metoclopramide Injection	Metoclopramide Injection The therapeutic efficacy of Disopyramide can be decreased when used in combination with Metoclopramide.
Metronidazole Injection	Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Disopyramide.
Morphine Injection	Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Disopyramide.
Pamidronate Injection	Pamidronate Injection Pamidronic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Vancomycin Injection	Vancomycin Injection Disopyramide may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Altretamine	Altretamine Amphetamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Cefuroxime	Cefuroxime Cefuroxime may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cyclosporine	Cyclosporine Cyclosporine may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Ondansetron	Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Disopyramide.
Granisetron	Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Disopyramide.
Torsemide	Torsemide The therapeutic efficacy of Disopyramide can be increased when used in combination with Torasemide.
Olanzapine	Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Disopyramide.
Alosetron	Alosetron The metabolism of Disopyramide can be decreased when combined with Alosetron.
Dofetilide	Dofetilide Dofetilide may increase the arrhythmogenic activities of Disopyramide.
Entacapone	Entacapone Entacapone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Hydroxychloroquine	Hydroxychloroquine The therapeutic efficacy of Disopyramide can be increased when used in combination with Hydroxychloroquine.
Meloxicam	Meloxicam Meloxicam may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Oxcarbazepine	Oxcarbazepine Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Pantoprazole	Pantoprazole Pantoprazole may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Temozolomide	Temozolomide Disopyramide may decrease the excretion rate of Temozolomide which could result in a higher serum level.
Zaleplon	Zaleplon Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Anakinra	Anakinra The metabolism of Disopyramide can be increased when combined with Anakinra.
Desloratadine	Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Disopyramide.
Linezolid	Linezolid Linezolid may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Rivastigmine	Rivastigmine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Rivastigmine.
Trimipramine	Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Disopyramide.
Etanercept Injection	Etanercept Injection The metabolism of Disopyramide can be increased when combined with Etanercept.
Glycopyrrolate	Glycopyrrolate The risk or severity of adverse effects can be increased when Disopyramide is combined with Glycopyrronium.
Modafinil	Modafinil The metabolism of Disopyramide can be increased when combined with Armodafinil.
Perindopril	Perindopril Disopyramide may decrease the excretion rate of Perindopril which could result in a higher serum level.
Tenofovir	Tenofovir Tenofovir may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Choline Magnesium Trisalicylate	Choline Magnesium Trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Sirolimus	Sirolimus Sirolimus may increase the QTc-prolonging activities of Disopyramide.
Epinephrine Injection	Epinephrine Injection The therapeutic efficacy of Disopyramide can be decreased when used in combination with Epinephrine.
Eplerenone	Eplerenone Eplerenone may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram	Escitalopram The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Escitalopram.
Zonisamide	Zonisamide Zonisamide may increase the arrhythmogenic activities of Disopyramide.
Adalimumab Injection	Adalimumab Injection The metabolism of Disopyramide can be increased when combined with Adalimumab.
Aripiprazole	Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Disopyramide.
Atomoxetine	Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Disopyramide.
Dexmethylphenidate	Dexmethylphenidate Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Atazanavir	Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Disopyramide.
Almotriptan	Almotriptan Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.
Eletriptan	Eletriptan Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Mefloquine	Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Disopyramide.
Polyethylene Glycol 3350	Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Disopyramide.
Rosuvastatin	Rosuvastatin The therapeutic efficacy of Disopyramide can be increased when used in combination with Rosuvastatin.
Vardenafil	Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Disopyramide.
Alfuzosin	Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Disopyramide.
Emtricitabine	Emtricitabine Disopyramide may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
Interferon Beta-1a Subcutaneous Injection	Interferon Beta-1a Subcutaneous Injection The metabolism of Disopyramide can be decreased when combined with Interferon beta-1a.
Memantine	Memantine The serum concentration of Disopyramide can be increased when it is combined with Memantine.
Tegaserod	Tegaserod The metabolism of Tegaserod can be decreased when combined with Disopyramide.
Tadalafil	Tadalafil Disopyramide may decrease the excretion rate of Tadalafil which could result in a higher serum level.
Fosamprenavir	Fosamprenavir The therapeutic efficacy of Disopyramide can be decreased when used in combination with Fosamprenavir.
Frovatriptan	Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Disopyramide.
Gemifloxacin	Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Disopyramide.
Progesterone	Progesterone The therapeutic efficacy of Disopyramide can be decreased when used in combination with Progesterone.
Apomorphine Injection	Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Disopyramide.
Infliximab Injection	Infliximab Injection The metabolism of Disopyramide can be increased when combined with Infliximab.
Oxandrolone	Oxandrolone Oxandrolone may increase the hypoglycemic activities of Disopyramide.
Protriptyline	Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Disopyramide.
Duloxetine	Duloxetine The metabolism of Duloxetine can be decreased when combined with Disopyramide.
Norethindrone	Norethindrone The therapeutic efficacy of Disopyramide can be decreased when used in combination with Norethisterone.
Tinidazole	Tinidazole Disopyramide may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Trospium	Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Disopyramide.
Bosentan	Bosentan The therapeutic efficacy of Disopyramide can be increased when used in combination with Bosentan.
Cefditoren	Cefditoren Disopyramide may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cinacalcet	Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Disopyramide.
Cyanocobalamin Injection	Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Erlotinib	Erlotinib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Erlotinib.
Eszopiclone	Eszopiclone Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ganciclovir	Ganciclovir The risk or severity of adverse effects can be increased when Disopyramide is combined with Ganciclovir.
Insulin Aspart (rDNA Origin) Injection	Insulin Aspart (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin aspart.
Ribavirin	Ribavirin Disopyramide may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Solifenacin	Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Disopyramide.
Valganciclovir	Valganciclovir Disopyramide may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Voriconazole	Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Disopyramide.
Adefovir	Adefovir Adefovir may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Dextroamphetamine	Dextroamphetamine Amphetamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Entecavir	Entecavir The metabolism of Entecavir can be decreased when combined with Disopyramide.
Peginterferon Alfa-2a Injection	Peginterferon Alfa-2a Injection The metabolism of Disopyramide can be decreased when combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b (PEG-Intron)	Peginterferon Alfa-2b (PEG-Intron) The serum concentration of Disopyramide can be increased when it is combined with Peginterferon alfa-2b.
Pramlintide Injection	Pramlintide Injection The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Disopyramide.
Sodium Oxybate	Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Exenatide Injection	Exenatide Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Exenatide.
Ibandronate	Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Disopyramide.
Isocarboxazid	Isocarboxazid Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ramelteon	Ramelteon The metabolism of Ramelteon can be decreased when combined with Disopyramide.
Darifenacin	Darifenacin The risk or severity of adverse effects can be increased when Disopyramide is combined with Darifenacin.
Fentanyl	Fentanyl The risk or severity of adverse effects can be increased when Disopyramide is combined with Fentanyl.
Pregabalin	Pregabalin Pregabalin may increase the arrhythmogenic activities of Disopyramide.
Deferasirox	Deferasirox The serum concentration of Disopyramide can be increased when it is combined with Deferasirox.
Phenylephrine	Phenylephrine The metabolism of Disopyramide can be increased when combined with Phenylephrine.
Tipranavir	Tipranavir The therapeutic efficacy of Disopyramide can be decreased when used in combination with Tipranavir.
Felbamate	Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Disopyramide.
Insulin Detemir (rDNA Origin) Injection	Insulin Detemir (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin detemir.
Ranolazine	Ranolazine The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Disopyramide.
Abatacept Injection	Abatacept Injection The metabolism of Disopyramide can be increased when combined with Abatacept.
Rasagiline	Rasagiline The metabolism of Rasagiline can be decreased when combined with Disopyramide.
Imatinib	Imatinib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Imatinib.
Sitagliptin	Sitagliptin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Sitagliptin.
Varenicline	Varenicline The excretion of Varenicline can be decreased when combined with Disopyramide.
Albuterol	Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Disopyramide.
Paliperidone	Paliperidone The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Paliperidone.
Bortezomib	Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Disopyramide.
Clofarabine Injection	Clofarabine Injection The serum concentration of Clofarabine can be increased when it is combined with Disopyramide.
Insulin Glulisine (rDNA origin) Injection	Insulin Glulisine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin glulisine.
Lubiprostone	Lubiprostone Disopyramide may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Oxaliplatin Injection	Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Disopyramide.
Posaconazole	Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Disopyramide.
Primaquine	Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Disopyramide.
Bismuth Subsalicylate	Bismuth Subsalicylate Bismuth subsalicylate may increase the hypoglycemic activities of Disopyramide.
Darunavir	Darunavir The therapeutic efficacy of Disopyramide can be decreased when used in combination with Darunavir.
Pemetrexed Injection	Pemetrexed Injection Disopyramide may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate	Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Disopyramide.
Lisdexamfetamine	Lisdexamfetamine The risk or severity of Tachycardia can be increased when Disopyramide is combined with Lisdexamfetamine.
Nabilone	Nabilone The risk or severity of Tachycardia and drowsiness can be increased when Disopyramide is combined with Nabilone.
Vorinostat	Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Disopyramide.
Sorafenib	Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Disopyramide.
Sunitinib	Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Disopyramide.
Dronabinol	Dronabinol The risk or severity of Tachycardia and drowsiness can be increased when Disopyramide is combined with Dronabinol.
Lapatinib	Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Disopyramide.
Levocetirizine	Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Disopyramide.
Pegaptanib Injection	Pegaptanib Injection Disopyramide may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Dasatinib	Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Disopyramide.
Mexiletine	Mexiletine Mexiletine may increase the arrhythmogenic activities of Disopyramide.
Armodafinil	Armodafinil The metabolism of Disopyramide can be increased when combined with Armodafinil.
Azacitidine Injection	Azacitidine Injection Disopyramide may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Paclitaxel (with polyoxyethylated castor oil) Injection	Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Disopyramide.
Temsirolimus	Temsirolimus Temsirolimus may increase the QTc-prolonging activities of Disopyramide.
Lenalidomide	Lenalidomide Disopyramide may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
Nilotinib	Nilotinib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Nilotinib.
Toremifene	Toremifene The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Toremifene.
Budesonide	Budesonide The risk or severity of hyperglycemia can be increased when Budesonide is combined with Disopyramide.
Desmopressin	Desmopressin Desmopressin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Betaine	Betaine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Glycine betaine.
OnabotulinumtoxinA Injection	OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum toxin type A.
RimabotulinumtoxinB Injection	RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum Toxin Type B.
Doripenem Injection	Doripenem Injection Disopyramide may decrease the excretion rate of Doripenem which could result in a higher serum level.
Arsenic Trioxide Injection	Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Arsenic trioxide.
Desvenlafaxine	Desvenlafaxine Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Desvenlafaxine.
Cevimeline	Cevimeline Cevimeline may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Nebivolol	Nebivolol Disopyramide may increase the bradycardic activities of Nebivolol.
Bendamustine Injection	Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Disopyramide.
Flecainide	Flecainide Flecainide may increase the arrhythmogenic activities of Disopyramide.
Certolizumab Injection	Certolizumab Injection The metabolism of Disopyramide can be increased when combined with Certolizumab pegol.
Ixabepilone Injection	Ixabepilone Injection Ixabepilone may increase the QTc-prolonging activities of Disopyramide.
Daptomycin Injection	Daptomycin Injection Daptomycin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Praziquantel	Praziquantel The metabolism of Praziquantel can be decreased when combined with Disopyramide.
Methylnaltrexone Injection	Methylnaltrexone Injection Disopyramide may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Rufinamide	Rufinamide Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Midazolam	Midazolam Midazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Naltrexone Injection	Naltrexone Injection The risk or severity of adverse effects can be increased when Disopyramide is combined with Naltrexone.
Dexrazoxane Injection	Dexrazoxane Injection Disopyramide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Eltrombopag	Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Disopyramide.
Milnacipran	Milnacipran Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Milnacipran.
Plerixafor Injection	Plerixafor Injection Disopyramide may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Sodium Phosphate	Sodium Phosphate The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Disopyramide.
Fesoterodine	Fesoterodine Disopyramide may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Degarelix Injection	Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Disopyramide.
Betaxolol	Betaxolol Disopyramide may increase the bradycardic activities of Betaxolol.
Iloperidone	Iloperidone The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Iloperidone.
Prasugrel	Prasugrel Disopyramide may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Lacosamide	Lacosamide Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Everolimus	Everolimus Everolimus may increase the QTc-prolonging activities of Disopyramide.
Tolvaptan (low blood sodium)	Tolvaptan (low blood sodium) Tolvaptan may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Dronedarone	Dronedarone Disopyramide may increase the QTc-prolonging activities of Dronedarone.
AbobotulinumtoxinA Injection	AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum toxin type A.
Pralatrexate Injection	Pralatrexate Injection Disopyramide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron Injection	Palonosetron Injection Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Palonosetron.
Saxagliptin	Saxagliptin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Saxagliptin.
Telavancin Injection	Telavancin Injection The risk or severity of QTc prolongation can be increased when Telavancin is combined with Disopyramide.
Romidepsin Injection	Romidepsin Injection The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Romidepsin.
Tapentadol	Tapentadol The risk or severity of adverse effects can be increased when Tapentadol is combined with Disopyramide.
Topotecan	Topotecan Disopyramide may decrease the excretion rate of Topotecan which could result in a higher serum level.
Golimumab Injection	Golimumab Injection The metabolism of Disopyramide can be increased when combined with Golimumab.
Pazopanib	Pazopanib The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Disopyramide.
Asenapine	Asenapine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Asenapine.
Vigabatrin	Vigabatrin Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Albendazole	Albendazole The metabolism of Albendazole can be decreased when combined with Disopyramide.
Levonorgestrel	Levonorgestrel The therapeutic efficacy of Disopyramide can be decreased when used in combination with Levonorgestrel.
Oxymorphone	Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Disopyramide.
Liraglutide Injection	Liraglutide Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Liraglutide.
Tocilizumab Injection	Tocilizumab Injection The metabolism of Disopyramide can be increased when combined with Tocilizumab.
Dalfampridine	Dalfampridine The serum concentration of Dalfampridine can be increased when it is combined with Disopyramide.
Fingolimod	Fingolimod Fingolimod may increase the arrhythmogenic activities of Disopyramide.
Eribulin Injection	Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Disopyramide.
IncobotulinumtoxinA Injection	IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum toxin type A.
Ceftaroline Injection	Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Lurasidone	Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Disopyramide.
Acetaminophen Injection	Acetaminophen Injection The metabolism of Acetaminophen can be decreased when combined with Disopyramide.
Vilazodone	Vilazodone Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ipilimumab Injection	Ipilimumab Injection Disopyramide may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Denileukin Diftitox Injection	Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Terbutaline Injection	Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Disopyramide.
Roflumilast	Roflumilast Disopyramide may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Linagliptin	Linagliptin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Linagliptin.
Rilpivirine	Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Disopyramide.
Abiraterone	Abiraterone The serum concentration of Disopyramide can be increased when it is combined with Abiraterone.
Triptorelin Injection	Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Disopyramide.
Rivaroxaban	Rivaroxaban Disopyramide may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Ruxolitinib	Ruxolitinib Disopyramide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Vandetanib	Vandetanib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Vandetanib.
Clobazam	Clobazam Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Clobazam.
Vemurafenib	Vemurafenib The serum concentration of Disopyramide can be increased when it is combined with Vemurafenib.
Deferiprone	Deferiprone Disopyramide may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Axitinib	Axitinib The metabolism of Axitinib can be decreased when combined with Disopyramide.
Crizotinib	Crizotinib The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Disopyramide.
Cabergoline	Cabergoline Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Naloxone Injection	Naloxone Injection Disopyramide may decrease the excretion rate of Naloxone which could result in a higher serum level.
Fondaparinux Injection	Fondaparinux Injection Disopyramide may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Ezogabine	Ezogabine Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Enzalutamide	Enzalutamide Disopyramide may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Mirabegron	Mirabegron The risk or severity of urinary retention can be increased when Disopyramide is combined with Mirabegron.
Corticotropin, Repository Injection	Corticotropin, Repository Injection The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Disopyramide.
Linaclotide	Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Disopyramide.
Teriflunomide	Teriflunomide The serum concentration of Disopyramide can be decreased when it is combined with Teriflunomide.
Lorcaserin	Lorcaserin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Mecasermin.
Teduglutide Injection	Teduglutide Injection Disopyramide may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Bedaquiline	Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Disopyramide.
Alogliptin	Alogliptin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Alogliptin.
Pomalidomide	Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Disopyramide.
Canagliflozin	Canagliflozin Canagliflozin may increase the hypoglycemic activities of Disopyramide.
Methazolamide	Methazolamide Methazolamide may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib	Dabrafenib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Disopyramide.
Trametinib	Trametinib Disopyramide may decrease the excretion rate of Trametinib which could result in a higher serum level.
Levomilnacipran	Levomilnacipran Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Ertapenem Injection	Ertapenem Injection Disopyramide may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Vortioxetine	Vortioxetine Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.
Perampanel	Perampanel The metabolism of Perampanel can be decreased when combined with Disopyramide.
Ketorolac Injection	Ketorolac Injection Ketorolac may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Simeprevir	Simeprevir The metabolism of Disopyramide can be decreased when combined with Simeprevir.
Sofosbuvir	Sofosbuvir Disopyramide may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Dapagliflozin	Dapagliflozin Dapagliflozin may increase the hypoglycemic activities of Disopyramide.
Apremilast	Apremilast The metabolism of Disopyramide can be increased when combined with Apremilast.
Droxidopa	Droxidopa Disopyramide may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Ceritinib	Ceritinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Disopyramide.
Siltuximab Injection	Siltuximab Injection The metabolism of Disopyramide can be increased when combined with Siltuximab.
Albiglutide Injection	Albiglutide Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Albiglutide.
Eslicarbazepine	Eslicarbazepine Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Belinostat Injection	Belinostat Injection The metabolism of Disopyramide can be increased when combined with Belinostat.
Testosterone Injection	Testosterone Injection Disopyramide may decrease the excretion rate of Testosterone which could result in a higher serum level.
Empagliflozin	Empagliflozin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Empagliflozin.
Hydrocodone	Hydrocodone The risk or severity of adverse effects can be increased when Hydrocodone is combined with Disopyramide.
Suvorexant	Suvorexant Suvorexant may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Dulaglutide Injection	Dulaglutide Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Dulaglutide.
Edoxaban	Edoxaban Disopyramide may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Peginterferon Beta-1a Injection	Peginterferon Beta-1a Injection The metabolism of Disopyramide can be decreased when combined with Peginterferon beta-1a.
Methamphetamine	Methamphetamine Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Metamfetamine.
Tasimelteon	Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Disopyramide.
Lanreotide Injection	Lanreotide Injection The therapeutic efficacy of Disopyramide can be decreased when used in combination with Lanreotide.
Pirfenidone	Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Disopyramide.
Secukinumab Injection	Secukinumab Injection The metabolism of Disopyramide can be increased when combined with Secukinumab.
Risperidone Injection	Risperidone Injection The risk or severity of QTc prolongation can be increased when Risperidone is combined with Disopyramide.
Insulin Human Inhalation	Insulin Human Inhalation The risk or severity of hypoglycemia can be increased when Insulin human is combined with Disopyramide.
Lenvatinib	Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Disopyramide.
Panobinostat	Panobinostat The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Disopyramide.
Haloperidol Injection	Haloperidol Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Disopyramide.
Ivabradine	Ivabradine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Ivabradine.
Amiloride	Amiloride Amiloride may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Macitentan	Macitentan Disopyramide may decrease the excretion rate of Macitentan which could result in a higher serum level.
Flibanserin	Flibanserin Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Prednisolone	Prednisolone The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Disopyramide.
Brexpiprazole	Brexpiprazole The therapeutic efficacy of Disopyramide can be decreased when used in combination with Brexpiprazole.
Ziprasidone Injection	Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Disopyramide.
Cariprazine	Cariprazine Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Penicillin G Procaine Injection	Penicillin G Procaine Injection Disopyramide may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Eluxadoline	Eluxadoline The risk or severity of constipation can be increased when Disopyramide is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection	Insulin Degludec (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin degludec.
Osimertinib	Osimertinib The serum concentration of Disopyramide can be decreased when it is combined with Osimertinib.
Ixazomib	Ixazomib Disopyramide may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Lesinurad	Lesinurad Disopyramide may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection	Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Dexamethasone Injection	Dexamethasone Injection The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Disopyramide.
Brivaracetam Injection	Brivaracetam Injection Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Midodrine	Midodrine The risk or severity of Tachycardia can be increased when Midodrine is combined with Disopyramide.
Pimavanserin	Pimavanserin Pimavanserin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Obeticholic Acid	Obeticholic Acid The metabolism of Disopyramide can be decreased when combined with Obeticholic acid.
Diphenhydramine Injection	Diphenhydramine Injection The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Disopyramide.
Furosemide Injection	Furosemide Injection The therapeutic efficacy of Disopyramide can be increased when used in combination with Furosemide.
Rucaparib	Rucaparib The metabolism of Rucaparib can be decreased when combined with Disopyramide.
Lixisenatide Injection	Lixisenatide Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Lixisenatide.
Ribociclib	Ribociclib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Ribociclib.
Doxepin (Insomnia)	Doxepin (Insomnia) Doxepin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Plecanatide	Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Disopyramide.
Deutetrabenazine	Deutetrabenazine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Deutetrabenazine.
Valbenazine	Valbenazine Disopyramide may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Deflazacort	Deflazacort The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Disopyramide.
Safinamide	Safinamide The metabolism of Disopyramide can be decreased when combined with Safinamide.
Naldemedine	Naldemedine Disopyramide may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Midostaurin	Midostaurin The metabolism of Disopyramide can be decreased when combined with Midostaurin.
Enasidenib	Enasidenib The metabolism of Disopyramide can be decreased when combined with Enasidenib.
Benznidazole	Benznidazole Disopyramide may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Delafloxacin	Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Disopyramide.
Semaglutide Injection	Semaglutide Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Semaglutide.
Tetrabenazine	Tetrabenazine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Tetrabenazine.
Ertugliflozin	Ertugliflozin The therapeutic efficacy of Disopyramide can be increased when used in combination with Ertugliflozin.
Buprenorphine Injection	Buprenorphine Injection The risk or severity of adverse effects can be increased when Buprenorphine is combined with Disopyramide.
Apalutamide	Apalutamide Disopyramide may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Baricitinib	Baricitinib Disopyramide may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Lofexidine	Lofexidine The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Disopyramide.
Plazomicin Injection	Plazomicin Injection Disopyramide may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat	Eliglustat The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Eliglustat.
Encorafenib	Encorafenib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Disopyramide.
Binimetinib	Binimetinib The metabolism of Binimetinib can be decreased when combined with Disopyramide.
Ivosidenib	Ivosidenib The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Disopyramide.
Cannabidiol	Cannabidiol The risk or severity of Tachycardia and drowsiness can be increased when Disopyramide is combined with Cannabidiol.
Stiripentol	Stiripentol The metabolism of Disopyramide can be decreased when combined with Stiripentol.
Gilteritinib	Gilteritinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Disopyramide.
Glasdegib	Glasdegib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Glasdegib.
Rifamycin	Rifamycin The metabolism of Disopyramide can be decreased when combined with Rifamycin.
Prucalopride	Prucalopride Disopyramide may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Magnesium Citrate	Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Disopyramide.
Emapalumab-lzsg Injection	Emapalumab-lzsg Injection The metabolism of Disopyramide can be increased when combined with Emapalumab.
Acyclovir Ophthalmic	Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Brexanolone Injection	Brexanolone Injection Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Solriamfetol	Solriamfetol The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Disopyramide.
Triclabendazole	Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Disopyramide.
Entrectinib	Entrectinib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Entrectinib.
Istradefylline	Istradefylline The metabolism of Istradefylline can be decreased when combined with Disopyramide.
Pitolisant	Pitolisant The serum concentration of Disopyramide can be decreased when it is combined with Pitolisant.
Lefamulin	Lefamulin Lefamulin may increase the QTc-prolonging activities of Disopyramide.
Phenytoin Injection	Phenytoin Injection The serum concentration of Disopyramide can be decreased when it is combined with Phenytoin.
Fosphenytoin Injection	Fosphenytoin Injection The serum concentration of Disopyramide can be decreased when it is combined with Fosphenytoin.
Lumateperone	Lumateperone Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Lasmiditan	Lasmiditan Lasmiditan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Cenobamate	Cenobamate The serum concentration of Disopyramide can be decreased when it is combined with Cenobamate.
Teprotumumab-trbw Injection	Teprotumumab-trbw Injection The therapeutic efficacy of Disopyramide can be decreased when used in combination with Teprotumumab.
Selumetinib	Selumetinib The metabolism of Selumetinib can be decreased when combined with Disopyramide.
Tucatinib	Tucatinib The metabolism of Tucatinib can be decreased when combined with Disopyramide.
Capmatinib	Capmatinib The metabolism of Disopyramide can be decreased when combined with Capmatinib.
Lemborexant	Lemborexant Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Fenfluramine	Fenfluramine Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Fostemsavir	Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Disopyramide.
Octreotide	Octreotide The therapeutic efficacy of Disopyramide can be decreased when used in combination with Octreotide.
Satralizumab-mwge Injection	Satralizumab-mwge Injection The serum concentration of Disopyramide can be decreased when it is combined with Satralizumab.
Relugolix	Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Disopyramide.
Progestin-Only (drospirenone) Oral Contraceptives	Progestin-Only (drospirenone) Oral Contraceptives The therapeutic efficacy of Disopyramide can be decreased when used in combination with Drospirenone.
Viloxazine	Viloxazine Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Viloxazine.
Tobramycin Injection	Tobramycin Injection Tobramycin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Theophylline	Theophylline The metabolism of Disopyramide can be decreased when combined with Theophylline.
Fenoprofen	Fenoprofen Fenoprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Indomethacin	Indomethacin Indomethacin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Mefenamic Acid	Mefenamic Acid Mefenamic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Naproxen	Naproxen Naproxen may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Tolmetin	Tolmetin Tolmetin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Sulindac	Sulindac Sulindac may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Trazodone	Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Disopyramide.
Isotretinoin	Isotretinoin Disopyramide may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Sucralfate	Sucralfate Disopyramide may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Floxuridine	Floxuridine Disopyramide may decrease the excretion rate of Floxuridine which could result in a higher serum level.
Phenobarbital	Phenobarbital Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Metaxalone	Metaxalone Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Methotrexate Injection	Methotrexate Injection Methotrexate may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Levorphanol	Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Disopyramide.
Primidone	Primidone The metabolism of Disopyramide can be increased when combined with Primidone.
Methsuximide	Methsuximide Methsuximide may increase the arrhythmogenic activities of Disopyramide.
Diethylpropion	Diethylpropion Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Chlorpromazine	Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Disopyramide.
Diazepam	Diazepam Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
Oxazepam	Oxazepam Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Flurazepam	Flurazepam Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Clorazepate	Clorazepate Clorazepic acid may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Lorazepam	Lorazepam Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Carmustine	Carmustine The metabolism of Disopyramide can be decreased when combined with Carmustine.
Amantadine	Amantadine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Amantadine.
Codeine	Codeine The risk or severity of adverse effects can be increased when Disopyramide is combined with Codeine.
Meprobamate	Meprobamate Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Chlordiazepoxide	Chlordiazepoxide Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Bromocriptine	Bromocriptine The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Bromocriptine.
Metaproterenol	Metaproterenol The risk or severity of Tachycardia can be increased when Disopyramide is combined with Orciprenaline.
Tranylcypromine	Tranylcypromine The metabolism of Disopyramide can be decreased when combined with Tranylcypromine.
Phenelzine	Phenelzine Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Phenelzine.
Procarbazine	Procarbazine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ergoloid Mesylates	Ergoloid Mesylates Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Tetracycline	Tetracycline Disopyramide may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Prochlorperazine	Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Disopyramide.
Thioridazine	Thioridazine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Thioridazine.
Trifluoperazine	Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Disopyramide.
Bleomycin	Bleomycin Disopyramide may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Sulfadiazine	Sulfadiazine The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfadiazine.
Oxycodone	Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Disopyramide.
Methadone	Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Disopyramide.
Oxybutynin	Oxybutynin The risk or severity of adverse effects can be increased when Disopyramide is combined with Oxybutynin.
Benztropine	Benztropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Disopyramide.
Maprotiline	Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Disopyramide.
Ibuprofen	Ibuprofen Ibuprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Trihexyphenidyl	Trihexyphenidyl The risk or severity of adverse effects can be increased when Disopyramide is combined with Trihexyphenidyl.
Orphenadrine	Orphenadrine The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Disopyramide.
Perphenazine	Perphenazine The metabolism of Perphenazine can be decreased when combined with Disopyramide.
Azathioprine	Azathioprine The metabolism of Azathioprine can be decreased when combined with Disopyramide.
Fluphenazine	Fluphenazine Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Phentermine	Phentermine The therapeutic efficacy of Disopyramide can be increased when used in combination with Phentermine.
Methylphenidate	Methylphenidate Disopyramide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Amoxapine	Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Disopyramide.
Sulfasalazine	Sulfasalazine Sulfasalazine may increase the hypoglycemic activities of Disopyramide.
Hydrocortisone	Hydrocortisone The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Disopyramide.
Cytarabine	Cytarabine The risk or severity of adverse effects can be increased when Disopyramide is combined with Cytarabine.
Mechlorethamine	Mechlorethamine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Mechlorethamine.
Pyridostigmine	Pyridostigmine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Pyridostigmine.
Phenazopyridine	Phenazopyridine Phenazopyridine may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Carbamazepine	Carbamazepine The metabolism of Disopyramide can be increased when combined with Carbamazepine.
Molindone	Molindone Molindone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Methyldopa	Methyldopa Disopyramide may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Clonidine	Clonidine The metabolism of Clonidine can be decreased when combined with Disopyramide.
Prazosin	Prazosin The serum concentration of Prazosin can be increased when it is combined with Disopyramide.
Hydralazine	Hydralazine Disopyramide may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Cimetidine	Cimetidine The serum concentration of Cimetidine can be increased when it is combined with Disopyramide.
Gentamicin Injection	Gentamicin Injection Gentamicin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Warfarin	Warfarin Disopyramide may decrease the excretion rate of Warfarin which could result in a higher serum level.
Clonazepam	Clonazepam Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Loperamide	Loperamide Loperamide may increase the arrhythmogenic activities of Disopyramide.
Promethazine	Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Disopyramide.
Meclofenamate	Meclofenamate Meclofenamic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Nitrofurantoin	Nitrofurantoin Disopyramide may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Griseofulvin	Griseofulvin The metabolism of Disopyramide can be increased when combined with Griseofulvin.
Digoxin	Digoxin Digoxin may increase the arrhythmogenic activities of Disopyramide.
Loxapine	Loxapine Loxapine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Chloroquine	Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Disopyramide.
Quinine	Quinine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Quinine.
Ethosuximide	Ethosuximide Ethosuximide may increase the arrhythmogenic activities of Disopyramide.
Triamterene	Triamterene The metabolism of Triamterene can be decreased when combined with Disopyramide.
Lactulose	Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Disopyramide.
Chlorothiazide	Chlorothiazide The therapeutic efficacy of Disopyramide can be decreased when used in combination with Chlorothiazide.
Chlorthalidone	Chlorthalidone The therapeutic efficacy of Disopyramide can be decreased when used in combination with Chlorthalidone.
Metolazone	Metolazone The therapeutic efficacy of Disopyramide can be decreased when used in combination with Metolazone.
Isosorbide	Isosorbide Isosorbide may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Clindamycin Injection	Clindamycin Injection Clindamycin may increase the QTc-prolonging activities of Disopyramide.
Secobarbital	Secobarbital Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
Desipramine	Desipramine Desipramine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Amitriptyline	Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Disopyramide.
Imipramine	Imipramine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Disopyramide.
Probenecid	Probenecid The therapeutic efficacy of Disopyramide can be increased when used in combination with Probenecid.
Quinidine	Quinidine Disopyramide may increase the arrhythmogenic activities of Quinidine.
Procainamide	Procainamide Disopyramide may increase the arrhythmogenic activities of Procainamide.
Isoniazid	Isoniazid The metabolism of Isoniazid can be decreased when combined with Disopyramide.
Pyrazinamide	Pyrazinamide Disopyramide may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
Rifampin	Rifampin The metabolism of Disopyramide can be increased when combined with Rifampicin.
Valproic Acid	Valproic Acid The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Valproic acid.
Tamoxifen	Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Disopyramide.
Butabarbital	Butabarbital Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Levothyroxine	Levothyroxine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Levothyroxine.
Liothyronine	Liothyronine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Liothyronine.
Methimazole	Methimazole The metabolism of Disopyramide can be decreased when combined with Methimazole.
Chlorpropamide	Chlorpropamide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Chlorpropamide.
Glucagon Injection	Glucagon Injection Disopyramide may increase the gastrointestinal motility reducing activities of Glucagon.
Tolbutamide	Tolbutamide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Tolbutamide.
Tolazamide	Tolazamide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Tolazamide.
Dextromethorphan	Dextromethorphan Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Cyclobenzaprine	Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Disopyramide.
Niacin	Niacin The therapeutic efficacy of Disopyramide can be decreased when used in combination with Niacin.
Baclofen	Baclofen The therapeutic efficacy of Disopyramide can be decreased when used in combination with Baclofen.
Doxylamine	Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Disopyramide.
Cyproheptadine	Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Disopyramide.
Clemastine	Clemastine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Clemastine.
Chlorpheniramine	Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Disopyramide.
Brompheniramine	Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Disopyramide.
Meclizine	Meclizine Meclizine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ethambutol	Ethambutol Disopyramide may decrease the excretion rate of Ethambutol which could result in a higher serum level.
Methyclothiazide	Methyclothiazide The therapeutic efficacy of Disopyramide can be decreased when used in combination with Methyclothiazide.
Hydrochlorothiazide	Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Disopyramide.
Dantrolene	Dantrolene Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Chlorzoxazone	Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Disopyramide.
Carisoprodol	Carisoprodol Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Methocarbamol	Methocarbamol Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Pyridoxine	Pyridoxine Pyridoxine may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Folic Acid	Folic Acid Folic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Danazol	Danazol The therapeutic efficacy of Disopyramide can be decreased when used in combination with Danazol.
Disulfiram	Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Disopyramide.
Propranolol (Cardiovascular)	Propranolol (Cardiovascular) Disopyramide may increase the bradycardic activities of Propranolol.
Pseudoephedrine	Pseudoephedrine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Pseudoephedrine.
Nortriptyline	Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Disopyramide.
Spironolactone	Spironolactone Spironolactone may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection	Amphotericin B Injection Amphotericin B may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Phytonadione	Phytonadione Disopyramide may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Amikacin Injection	Amikacin Injection Amikacin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Nadolol	Nadolol Disopyramide may increase the bradycardic activities of Nadolol.
Butorphanol Injection	Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Disopyramide.
Nalbuphine Injection	Nalbuphine Injection The risk or severity of adverse effects can be increased when Nalbuphine is combined with Disopyramide.
Allopurinol	Allopurinol Disopyramide may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Oxytocin Injection	Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Disopyramide.
Fluoxymesterone	Fluoxymesterone Fluoxymesterone may increase the hypoglycemic activities of Disopyramide.
Trimethobenzamide	Trimethobenzamide Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Flavoxate	Flavoxate Disopyramide may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Papaverine	Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Disopyramide.
Fluorouracil Injection	Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Disopyramide.
Colchicine	Colchicine Disopyramide may decrease the excretion rate of Colchicine which could result in a higher serum level.
Cefaclor	Cefaclor Cefaclor may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cefadroxil	Cefadroxil Cefadroxil may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cefazolin Injection	Cefazolin Injection Cefazolin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cephalexin	Cephalexin Cephalexin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cefoxitin Injection	Cefoxitin Injection Cefoxitin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Dacarbazine	Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Disopyramide.
Acetazolamide	Acetazolamide The therapeutic efficacy of Disopyramide can be increased when used in combination with Acetazolamide.
Cefotaxime Injection	Cefotaxime Injection Cefotaxime may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Calcitonin Salmon Injection	Calcitonin Salmon Injection Salmon calcitonin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Ketoconazole	Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Disopyramide.
Pyrantel	Pyrantel Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Thiotepa Injection	Thiotepa Injection The therapeutic efficacy of Disopyramide can be decreased when used in combination with Thiotepa.
Isoxsuprine	Isoxsuprine The risk or severity of Tachycardia can be increased when Disopyramide is combined with Isoxsuprine.
Ethacrynic Acid	Ethacrynic Acid The therapeutic efficacy of Disopyramide can be decreased when used in combination with Etacrynic acid.
Colistimethate Injection	Colistimethate Injection Colistimethate may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Metoprolol	Metoprolol Disopyramide may increase the bradycardic activities of Metoprolol.
Hydroxyzine	Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Disopyramide.
Thiothixene	Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Disopyramide.
Aspirin	Aspirin The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Disopyramide.
Salsalate	Salsalate Salsalate may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Alprazolam	Alprazolam Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Temazepam	Temazepam Temazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Triazolam	Triazolam Triazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Dicyclomine	Dicyclomine Disopyramide may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Hyoscyamine	Hyoscyamine Hyoscyamine may increase the arrhythmogenic activities of Disopyramide.
Propantheline	Propantheline Disopyramide may decrease the excretion rate of Propantheline which could result in a higher serum level.
Trimethoprim	Trimethoprim Disopyramide may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
Diltiazem	Diltiazem Diltiazem may increase the arrhythmogenic activities of Disopyramide.
Nifedipine	Nifedipine Nifedipine may increase the arrhythmogenic activities of Disopyramide.
Timolol	Timolol Disopyramide may increase the bradycardic activities of Timolol.
Verapamil	Verapamil The risk or severity of sinus node depression can be increased when Verapamil is combined with Disopyramide.
Atenolol	Atenolol Disopyramide may increase the bradycardic activities of Atenolol.
Pindolol	Pindolol Disopyramide may increase the bradycardic activities of Pindolol.
Cisplatin Injection	Cisplatin Injection The serum concentration of Disopyramide can be increased when it is combined with Cisplatin.
Diflunisal	Diflunisal Diflunisal may increase the hypoglycemic activities of Disopyramide.
Piroxicam	Piroxicam Piroxicam may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Bumetanide	Bumetanide The therapeutic efficacy of Disopyramide can be increased when used in combination with Bumetanide.
Streptozocin	Streptozocin The metabolism of Disopyramide can be increased when combined with Streptozocin.
Etoposide	Etoposide The metabolism of Etoposide can be decreased when combined with Disopyramide.
Glyburide	Glyburide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Glyburide.
Glipizide	Glipizide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Glipizide.
Indapamide	Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Disopyramide.
Amoxicillin	Amoxicillin Disopyramide may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Nafcillin Injection	Nafcillin Injection The metabolism of Disopyramide can be increased when combined with Nafcillin.
Oxacillin Injection	Oxacillin Injection Disopyramide may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Pentoxifylline	Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Disopyramide.
Pentamidine Injection	Pentamidine Injection The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Disopyramide.
Ceftriaxone Injection	Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Labetalol	Labetalol Disopyramide may increase the bradycardic activities of Labetalol.
Auranofin	Auranofin Disopyramide may decrease the excretion rate of Auranofin which could result in a higher serum level.
Leuprolide Injection	Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Disopyramide.
Gemfibrozil	Gemfibrozil The metabolism of Disopyramide can be decreased when combined with Gemfibrozil.
Guanabenz	Guanabenz The metabolism of Guanabenz can be decreased when combined with Disopyramide.
Dipivefrin Ophthalmic	Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Ceftazidime Injection	Ceftazidime Injection Ceftazidime may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Ketoprofen	Ketoprofen Ketoprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cefotetan Injection	Cefotetan Injection Cefotetan may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Pimozide	Pimozide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Pimozide.
Flurbiprofen	Flurbiprofen Flurbiprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Amiodarone	Amiodarone Amiodarone may increase the QTc-prolonging activities of Disopyramide.
Aztreonam Injection	Aztreonam Injection Disopyramide may decrease the excretion rate of Aztreonam which could result in a higher serum level.
Buspirone	Buspirone Disopyramide may decrease the excretion rate of Buspirone which could result in a higher serum level.
Ciprofloxacin	Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Disopyramide.
Mesalamine	Mesalamine Mesalazine may increase the hypoglycemic activities of Disopyramide.
Diclofenac	Diclofenac Diclofenac may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Fluoxetine	Fluoxetine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Fluoxetine.
Nimodipine	Nimodipine Nimodipine may increase the arrhythmogenic activities of Disopyramide.
Interferon Alfa-2b Injection	Interferon Alfa-2b Injection The metabolism of Disopyramide can be decreased when combined with Interferon alfa-2b.
Clozapine	Clozapine The risk or severity of QTc prolongation can be increased when Clozapine is combined with Disopyramide.
Estazolam	Estazolam Estazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ofloxacin	Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Disopyramide.
Didanosine	Didanosine Disopyramide may decrease the excretion rate of Didanosine which could result in a higher serum level.
Pentostatin Injection	Pentostatin Injection Disopyramide may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Clarithromycin	Clarithromycin Clarithromycin may increase the QTc-prolonging activities of Disopyramide.
Benazepril	Benazepril The risk or severity of hypoglycemia can be increased when Benazepril is combined with Disopyramide.
Etodolac	Etodolac Etodolac may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Felodipine	Felodipine Felodipine may increase the arrhythmogenic activities of Disopyramide.
Fosinopril	Fosinopril Disopyramide may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Nabumetone	Nabumetone Nabumetone may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Amlodipine	Amlodipine Amlodipine may increase the arrhythmogenic activities of Disopyramide.
Itraconazole	Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Disopyramide.
Lisinopril	Lisinopril Disopyramide may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Oxaprozin	Oxaprozin Oxaprozin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Sotalol	Sotalol The risk or severity of hypoglycemia can be increased when Sotalol is combined with Disopyramide.
Bisoprolol	Bisoprolol The therapeutic efficacy of Disopyramide can be increased when used in combination with Bisoprolol.
Zolpidem	Zolpidem The metabolism of Zolpidem can be decreased when combined with Disopyramide.
Isradipine	Isradipine Isradipine may increase the arrhythmogenic activities of Disopyramide.
Omeprazole	Omeprazole The metabolism of Disopyramide can be increased when combined with Omeprazole.
Cisapride	Cisapride The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Cisapride.
Gabapentin	Gabapentin Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Venlafaxine	Venlafaxine The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Disopyramide.
Nizatidine	Nizatidine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Nizatidine.
Fluvoxamine	Fluvoxamine The metabolism of Disopyramide can be decreased when combined with Fluvoxamine.
Nefazodone	Nefazodone The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Nefazodone.
Lamotrigine	Lamotrigine Lamotrigine may increase the arrhythmogenic activities of Disopyramide.
Losartan	Losartan Losartan may increase the arrhythmogenic activities of Disopyramide.
Valacyclovir	Valacyclovir Valaciclovir may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Tramadol	Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Disopyramide.
Carboplatin Injection	Carboplatin Injection Carboplatin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Moexipril	Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Disopyramide.
Ifosfamide Injection	Ifosfamide Injection Disopyramide may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
Nicardipine	Nicardipine Nicardipine may increase the arrhythmogenic activities of Disopyramide.
Bupropion	Bupropion Bupropion may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ticlopidine	Ticlopidine The metabolism of Disopyramide can be decreased when combined with Ticlopidine.
Saquinavir	Saquinavir The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Disopyramide.
Metformin	Metformin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Metformin.
Nisoldipine	Nisoldipine Disopyramide may increase the arrhythmogenic activities of Nisoldipine.
Lamivudine	Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Disopyramide.
Riluzole	Riluzole The metabolism of Riluzole can be decreased when combined with Disopyramide.
Acarbose	Acarbose The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Acarbose.
Glimepiride	Glimepiride Glimepiride may increase the arrhythmogenic activities of Disopyramide.
Gemcitabine Injection	Gemcitabine Injection Disopyramide may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
Indinavir	Indinavir The therapeutic efficacy of Disopyramide can be decreased when used in combination with Indinavir.
Ritonavir	Ritonavir The serum concentration of Disopyramide can be increased when it is combined with Ritonavir.
Cidofovir Injection	Cidofovir Injection Cidofovir may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Meropenem Injection	Meropenem Injection Disopyramide may decrease the excretion rate of Meropenem which could result in a higher serum level.
Clomipramine	Clomipramine The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Disopyramide.
Zafirlukast	Zafirlukast The metabolism of Disopyramide can be decreased when combined with Zafirlukast.
Fosfomycin	Fosfomycin Disopyramide may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Mirtazapine	Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Disopyramide.
Topiramate	Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Disopyramide is combined with Topiramate.
Zileuton	Zileuton The metabolism of Zileuton can be decreased when combined with Disopyramide.
Insulin Lispro Injection	Insulin Lispro Injection The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Disopyramide.
Pramipexole	Pramipexole The serum concentration of Pramipexole can be increased when it is combined with Disopyramide.
Donepezil	Donepezil The therapeutic efficacy of Disopyramide can be decreased when used in combination with Donepezil.
Nelfinavir	Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Disopyramide.
Azithromycin	Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Disopyramide.
Loratadine	Loratadine Disopyramide may increase the anticholinergic activities of Loratadine.
Carvedilol	Carvedilol Disopyramide may increase the bradycardic activities of Carvedilol.
Nilutamide	Nilutamide Disopyramide may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Flutamide	Flutamide The metabolism of Flutamide can be decreased when combined with Disopyramide.
Selegiline	Selegiline The metabolism of Disopyramide can be decreased when combined with Selegiline.
Sertraline	Sertraline Sertraline may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Propafenone	Propafenone Propafenone may increase the arrhythmogenic activities of Disopyramide.
Tamsulosin	Tamsulosin The therapeutic efficacy of Tamsulosin can be increased when used in combination with Disopyramide.
Ropinirole	Ropinirole Ropinirole may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Quetiapine	Quetiapine The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Disopyramide.
Cefepime Injection	Cefepime Injection Cefepime may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cefprozil	Cefprozil Cefprozil may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cefpodoxime	Cefpodoxime Cefpodoxime may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cetirizine	Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Disopyramide.
Paroxetine	Paroxetine Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Tolcapone	Tolcapone Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Citalopram	Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Disopyramide.
Capecitabine	Capecitabine Disopyramide may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Efavirenz	Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Disopyramide.
Abacavir	Abacavir Disopyramide may decrease the excretion rate of Abacavir which could result in a higher serum level.
Pioglitazone	Pioglitazone The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Pioglitazone.
Celecoxib	Celecoxib The therapeutic efficacy of Disopyramide can be increased when used in combination with Celecoxib.
Rosiglitazone	Rosiglitazone The metabolism of Disopyramide can be decreased when combined with Rosiglitazone.
Tolterodine	Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Disopyramide.
Thalidomide	Thalidomide Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Oseltamivir	Oseltamivir Oseltamivir may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Balsalazide	Balsalazide Balsalazide may increase the hypoglycemic activities of Disopyramide.
Nateglinide	Nateglinide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Nateglinide.
Galantamine	Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Disopyramide.
Levetiracetam	Levetiracetam Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Rabeprazole	Rabeprazole The metabolism of Rabeprazole can be increased when combined with Disopyramide.
Terbinafine	Terbinafine The metabolism of Terbinafine can be decreased when combined with Disopyramide.

Disopyramide

On this page